1. Revolution Medicines, Inc. (NASDAQ:RVMD)
Number of Hedge Fund Holders: 60
Enterprise Value: $4.93 billion
Market Capitalization: $7.08 billion
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage biotech company developing cancer drugs that target a key group of genetic mutations known as RAS, which are commonly found in difficult-to-treat tumors. The company uses proprietary technology to design small-molecule drugs that block these cancer-driving proteins. Its main drug candidates are in human trials and focus on types of lung and pancreatic cancer where current treatment options are limited. Based in California, RVMD aims to build a pipeline of precision therapies that could address a broad segment of the oncology market.
Revolution Medicines, Inc. (NASDAQ:RVMD) is making meaningful strides in addressing pancreatic cancer, a historically difficult-to-treat indication, with its lead candidate RMC-6236 (Daraxonrasib). The ongoing RASolute 302 trial is targeting second-line treatment in approximately 420 patients and is seeing strong enrollment momentum, with data readouts expected in 2026. Early clinical signals have been compelling, with median progression-free survival reaching 8.8 months and median overall survival extending to 14.5 months at the 300mg dose – markedly higher than the historical benchmarks of approximately 3 and 6 months, respectively. These data suggest the potential for material improvement over current standards of care.
Looking ahead, Revolution Medicines, Inc. (NASDAQ:RVMD) is broadening its pancreatic cancer pipeline by launching additional trials in 2025, including a first-line metastatic study and a trial in early-stage resectable disease for adjuvant use. Importantly for patient-centric outcomes, reported quality-of-life improvements such as reduced pain and weight gain support clinical value beyond survival metrics. RVMD is also advancing Zoldonrasib, a selective G12D inhibitor, which has shown promising monotherapy activity, with more data anticipated in the coming quarters. The company’s strategy includes developing RAS-targeted combination therapies, such as dual inhibitor regimens and collaborations with Tango Therapeutics, potentially enhancing durability and broadening the market opportunity.
Overall, Revolution Medicines, Inc. (NASDAQ:RVMD) ranks first on our list of the 10 best debt free mid cap stocks to buy now. While we acknowledge the potential of RVMD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RVMD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks To Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
